SecBot SecBot
PRESS-RELEASE ·Filed Apr 17, 2026

OLMA

Olema Oncology
MIXED
Impact 5/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ◆ Mixed

Traders should monitor upcoming top-line data from the Phase 3 OPERA-01 trial in fall 2026, which will be a key catalyst. While preclinical synergy is encouraging, the lack of clinical data for the OP-3136 combination means near-term upside is limited. Positive data could enhance partnership potential or valuation re-rating.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$16.58
T+0 close · Apr 17, 2026 · via day close
Latest settled
−28.71%
T+60 · $11.82
Vs SPY
−35.49%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 20 $16.58entry
  2. T+1 · 7mo ago +0.30%α +0.95% · $16.63
  3. T+5 · 7mo ago −7.78%α −8.69% · $15.29
  4. T+20 · 6mo ago −22.20%α −26.40% · $12.90
  5. T+60 · 4mo ago −28.71%α −35.49% · $11.82
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Olema Oncology released preclinical data showing palazestrant fully recruits the NCoR1 corepressor for complete estrogen receptor antagonism, and demonstrates synergistic anti-tumor activity when combined with OP-3136 in ER+/HER2- breast cancer models. The data support ongoing Phase 3 trials of palazestrant and the development of OP-3136 in combination therapy, though no clinical efficacy results were reported.

Key Facts

  • Preclinical data show palazestrant recruits NCoR1, enabling complete antagonism of estrogen receptor signaling in ER+/HER2- breast cancer models.
  • Combination of palazestrant and OP-3136 shows synergistic anti-tumor activity by suppressing cell-cycle and ER-driven oncogenic pathways.
  • Palazestrant is in two ongoing Phase 3 trials (OPERA-01 and OPERA-02); top-line data from OPERA-01 expected in fall 2026.
  • OP-3136, a KAT6 inhibitor, is in a Phase 1 trial with patient enrollment ongoing.
  • Data were presented at AACR 2026, but remain preclinical, no human efficacy or safety results from combinations were disclosed.

Financial Impact

No direct financial impact disclosed; potential long-term value in combination therapy development and differentiation of palazestrant.

pipeline valueR&D trajectorymarket differentiation

Risk Factors

  • Preclinical results may not translate to clinical efficacy in humans.
  • Delays or negative outcomes in Phase 3 trials (OPERA-01/02) could significantly impact valuation.
  • Competitive landscape includes approved SERDs and next-gen endocrine therapies with clinical validation.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3276477

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 17, 2026